Part I | Chapter 7 138 Characteristic Total group Toxicity + Toxicity - Number of patients, n (%) 130 (100) 39 (30) 91(70) Age in years, mean (SD) 69 (6) 68 (6) 69 (6) NCCN risk classification, n (%) Low 14 (10.8) 5 (12.8) 9 (9.9) Intermediate 109 (83.8) 30 (76.9) 79 (86.8) High 7 (5.4) 4 (10.3) 3 (3.3) Gleason score, n (%) 3 + 3 = 6 25 (19.2) 9 (23.1) 16 (17.6) 3 + 4 = 7 79 (60.8) 24 (61.5) 55 (60.4) 4 + 3 = 7 25 (19.2) 6 (15.4) 19 (20.9) 8 1 (0.8) 0 (0) 1 (1.1) cT-stage, n (%) cT1 66 (50.8) 20 (51.3) 46 (50.5) cT2 62 (47.7) 19 (48.7) 43 (47.3) cT3 2 (1.5) 0 (0) 2 (2.2) Diabetes Mellitus, n (%) No 123 (94.6) 36 (92.3) 87 (95.6) Yes 7 (5.4) 3 (7.7) 4 (4.6) Cardiovascular disease, n (%) No 117 (90.0) 37 (94.9) 80 (87.9) Yes 13 (10.0) 2 (5.1) 11 (12.1) Hormonal therapy, n (%) No 122 (93.8) 36 (92.3) 86 (94.5) Yes 8 (6.2) 3 (7.7) 5 (5.5) BL alpha-blocker usage, n (%) No 116 (89.2) 38 (97.4) 78 (85.7) Yes 14 (10.8) 1 (2.6) 13 (14.3) PTV in cm3, median (IQR) 100 (84-122) 114 (102-134) 93 (80-114) Mean* bladder volume in cm3, median (IQR) 153 (115-207) 137 (113-190) 162 (118-225) Mean* bladder wall volume in cm3, median (IQR) 41 (34-47) 40 (33-47) 41 (36-47) Baseline IPSS, median (IQR) 6 (4-10) 7 (4-9) 6 (3-11) Table 1 – Baseline patient, tumour, and treatment characteristics for the complete cohort and stratified by ‘IPSS+10 and/or start of alpha-blockers within 3 months’: yes (+) or no (-). *Over the five-course treatment. Legend: SD = Standard deviation. NCCN = National Comprehensive Cancer Network. BL = Baseline. PTV = Planning Target Volume. IQR = Interquartile range. IPSS = International Prostate Symptom Score.
RkJQdWJsaXNoZXIy MTk4NDMw